Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

CStone Pharma's (基石药业) Lock-Up Expiry - Analysis of Potential Selling Shareholders

CStone Pharma's (基石药业) Lock-Up Expiry - A Review of Valuation

CStone Pharma (基石药业) Post-IPO: Strong Debut but Lacks near Term Catalysts

CStone Pharma (基石药业) IPO: Thoughts on Valuation (Part 2)

CStone Pharma (基石药业) IPO: Strong Assembly and Backing (Part 1)

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

CStone Pharmaceuticals / Equity Capital Markets

Lock-up restriction for Cstone Pharma's pre-IPO investors and cornerstone investors will expire on August 26th.
As we expect roughly USD 1 billion worth of shares will be eligible for sale, we look at the company's recent development in this insight. 
Despite numerous updates announced by the company in the past six months, there is a lack of newsflows for core drug candidates and hence, a lack of catalyst for the stock price.

Lock-up restriction for Cstone Pharma's pre-IPO investors and cornerstone investors will expire on August 26th.
As we expect roughly USD 1 billion worth of shares will be eligible for sale, we look at the company's recent development in this insight. 
Despite numerous updates announced by the company in the past six months, there is a lack of newsflows for core drug candidates and hence, a lack of catalyst for the stock price. 

CStone Pharma's (基石药业) Lock-Up Expiry - Lack of Material Newsflow for Core Drug Candidates